Advances in the available pharmacotherapy for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
A Greco, S Finocchiaro, DJ Angiolillo… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Non-ST-segment elevation acute coronary syndromes (NSTE-ACS), including
non-ST-segment-elevation myocardial infarction (NSTEMI) and unstable angina, represent a …
non-ST-segment-elevation myocardial infarction (NSTEMI) and unstable angina, represent a …
Factors associated with platelet activation-recent pharmaceutical approaches
Platelets are at the forefront of human health and disease following the advances in their
research presented in past decades. Platelet activation, their most crucial function, although …
research presented in past decades. Platelet activation, their most crucial function, although …
Impact of the ABCD‐GENE score on clopidogrel clinical effectiveness after PCI: a multi‐site, real‐world investigation
The Age, Body mass index, Chronic kidney disease, Diabetes mellitus, and CYP2C19
GENEtic variants (ABCD‐GENE) score was developed to identify patients at risk for …
GENEtic variants (ABCD‐GENE) score was developed to identify patients at risk for …
Platelet reactivity and clinical outcomes after drug-eluting stent implantation: results from the PTRG-DES consortium
SJ Lee, JJ Cha, YH Jeong, SJ Hong, CM Ahn… - Cardiovascular …, 2022 - jacc.org
Background The long-term prognostic implication of platelet reactivity after percutaneous
coronary intervention (PCI) is not clearly known. Objectives The impacts of platelet reactivity …
coronary intervention (PCI) is not clearly known. Objectives The impacts of platelet reactivity …
Genetic-Guided Oral P2Y12 Inhibitor Selection and Cumulative Ischemic Events After Percutaneous Coronary Intervention
BS Ingraham, ME Farkouh, RJ Lennon, D So… - Cardiovascular …, 2023 - jacc.org
Abstract Background Genetic-guided P2Y12 inhibitor selection has been proposed to
reduce ischemic events by identifying CYP2C19 loss-of-function (LOF) carriers at increased …
reduce ischemic events by identifying CYP2C19 loss-of-function (LOF) carriers at increased …
Ticagrelor enhances the cardioprotective effects of ischemic preconditioning in stable patients undergoing percutaneous coronary intervention: the TAPER-S …
D D'Amario, M Galli, A Restivo… - European Heart …, 2024 - academic.oup.com
Background Ticagrelor improves clinical outcomes in patients with acute coronary
syndromes compared with clopidogrel. Ticagrelor also inhibits cell uptake of adenosine and …
syndromes compared with clopidogrel. Ticagrelor also inhibits cell uptake of adenosine and …
Impact of ethnicity on antiplatelet treatment regimens for bleeding reduction in acute coronary syndromes: a systematic review and pre-specified subgroup meta …
Abstract Aims Randomized controlled trials (RCTs) testing bleeding reduction strategies
using antiplatelet treatment regimens (BRATs) in acute coronary syndromes (ACS) have …
using antiplatelet treatment regimens (BRATs) in acute coronary syndromes (ACS) have …
[HTML][HTML] Gender-differences in antithrombotic therapy across the spectrum of ischemic heart disease: Time to tackle the Yentl syndrome?
The incidence and clinical presentation of ischemic heart disease (IHD), as well as
thrombotic and bleeding risks, appear to differ between genders. Compared with men …
thrombotic and bleeding risks, appear to differ between genders. Compared with men …
Effectiveness of Clopidogrel vs Alternative P2Y12 Inhibitors Based on the ABCD-GENE Score
Abstract Background An ABCD-GENE (age, body mass index, chronic kidney disease,
diabetes, and CYP2C19 genetic variants) score≥ 10 predicts reduced clopidogrel …
diabetes, and CYP2C19 genetic variants) score≥ 10 predicts reduced clopidogrel …
Bleeding in acute coronary syndrome: from definitions, incidence, and prognosis to prevention and management
C Laudani, D Capodanno… - Expert Opinion on Drug …, 2023 - Taylor & Francis
Introduction In patients with acute coronary syndrome (ACS), the ischemic benefit of
antithrombotic treatment is counterbalanced by the risk of bleeding. The recognition that …
antithrombotic treatment is counterbalanced by the risk of bleeding. The recognition that …